Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?

21 hours ago 1

Soumya Eswaran

Tue, December 30, 2025 astatine 6:33 AM CST 3 min read

Contrarius Investment Management, an concern absorption company, released its third-quarter capitalist missive for the “Contrarius Global Equity Fund”. A transcript of the missive tin beryllium downloaded here. The fund’s capitalist people returned 30.9% successful the September 4th compared to 7.3% for the benchmark MSCI World Index, including reinvested nett income, and 5.5% for the Average Global Equity Fund. The fund’s concern doctrine is autarkic of benchmark considerations, truthful the portfolios typically deviate from the benchmark World Index. Additionally, delight reappraisal the fund’s apical 5 holdings to spot its starring picks successful 2025.

In its third-quarter 2025 capitalist letter, Contrarius Global Equity Fund highlighted stocks specified arsenic Beam Therapeutics Inc. (NASDAQ:BEAM). Beam Therapeutics Inc. (NASDAQ:BEAM) is simply a biotechnology company, engages successful the improvement of precision familial medicines. The one-month instrumentality for Beam Therapeutics Inc. (NASDAQ:BEAM) was 19.13%, and its shares gained 12.26% of their worth implicit the past 52 weeks. On December 29, 2025, Beam Therapeutics Inc. (NASDAQ:BEAM) banal closed astatine $27.84 per share, with a marketplace capitalization of $2.83 billion.

Contrarius Global Equity Fund stated the pursuing regarding Beam Therapeutics Inc. (NASDAQ:BEAM) successful its 3rd 4th 2025 capitalist letter:

"Beam Therapeutics Inc. (NASDAQ:BEAM): There person been important further technological breakthroughs since CRISPR-Cas9 was archetypal discovered astir 13 years ago. Beam holds patents to 1 specified breakthrough, ‘base editing’ a.k.a. CRISPR 2.0.

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

Beam Therapeutics Inc. (NASDAQ:BEAM) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 27 hedge money portfolios held Beam Therapeutics Inc. (NASDAQ:BEAM) astatine the extremity of the 3rd quarter, compared to 31 successful the erstwhile quarter. While we admit the imaginable of Beam Therapeutics Inc. (NASDAQ:BEAM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.